236 related articles for article (PubMed ID: 24127173)
1. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice.
Rinotas V; Niti A; Dacquin R; Bonnet N; Stolina M; Han CY; Kostenuik P; Jurdic P; Ferrari S; Douni E
J Bone Miner Res; 2014; 29(5):1158-69. PubMed ID: 24127173
[TBL] [Abstract][Full Text] [Related]
2. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
3. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.
Helas S; Goettsch C; Schoppet M; Zeitz U; Hempel U; Morawietz H; Kostenuik PJ; Erben RG; Hofbauer LC
Am J Pathol; 2009 Aug; 175(2):473-8. PubMed ID: 19590040
[TBL] [Abstract][Full Text] [Related]
5. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.
Boyce RW; Varela A; Chouinard L; Bussiere JL; Chellman GJ; Ominsky MS; Pyrah IT
Bone; 2014 Jul; 64():314-25. PubMed ID: 24727159
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.
Mizuno A; Kanno T; Hoshi M; Shibata O; Yano K; Fujise N; Kinosaki M; Yamaguchi K; Tsuda E; Murakami A; Yasuda H; Higashio K
J Bone Miner Metab; 2002; 20(6):337-44. PubMed ID: 12434161
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis.
Leistner DM; Seeger FH; Fischer A; Röxe T; Klotsche J; Iekushi K; Seeger T; Assmus B; Honold J; Karakas M; Badenhoop K; Frantz S; Dimmeler S; Zeiher AM
Circ Heart Fail; 2012 Nov; 5(6):769-77. PubMed ID: 22936827
[TBL] [Abstract][Full Text] [Related]
10. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.
Bonnet N; Bourgoin L; Biver E; Douni E; Ferrari S
J Clin Invest; 2019 May; 129(8):3214-3223. PubMed ID: 31120440
[TBL] [Abstract][Full Text] [Related]
11. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification.
Osako MK; Nakagami H; Koibuchi N; Shimizu H; Nakagami F; Koriyama H; Shimamura M; Miyake T; Rakugi H; Morishita R
Circ Res; 2010 Aug; 107(4):466-75. PubMed ID: 20595654
[TBL] [Abstract][Full Text] [Related]
12. [Osteoporosis and RANKL signal].
Nakamura M; Udagawa N
Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
14. RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer.
Sato K; Lee JW; Sakamoto K; Iimura T; Kayamori K; Yasuda H; Shindoh M; Ito M; Omura K; Yamaguchi A
Am J Pathol; 2013 May; 182(5):1890-9. PubMed ID: 23499553
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
16. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF.
Douni E; Rinotas V; Makrinou E; Zwerina J; Penninger JM; Eliopoulos E; Schett G; Kollias G
Hum Mol Genet; 2012 Feb; 21(4):784-98. PubMed ID: 22068587
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis.
Onodera S; Sasaki S; Ohshima S; Amizuka N; Li M; Udagawa N; Irie K; Nishihira J; Koyama Y; Shiraishi A; Tohyama H; Yasuda K
J Bone Miner Res; 2006 Jun; 21(6):876-85. PubMed ID: 16753018
[TBL] [Abstract][Full Text] [Related]
18. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
19. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
20. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
